Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group

Robert A. Kyle, J. Anthony Child, Kenneth Anderson, Bart Barlogie, Regis Bataille, William Bensinger, Joan Bladé, Mario Boccadoro, William Dalton, Meletios Dimopoulos, Benjamin Djulbegovic, Mark Drayson, Brian Durie, Thiery Facon, Rafael Fonseca, Gosta Gahrton, Philip Greipp, Jean Luc Harousseau, David Harrington, Mohamad HusseinDouglas Joshua, Heinz Ludwig, Gareth Morgan, Martin Oken, Raymond Powles, Paul Richardson, G. David Roodman, Jesus San Miguel, Kazuyuki Shimizu, Chaim Shustik, Bhawna Sirohi, Pieter Sonneveld, Guido Tricot, Ingemar Turesson, Brian Van Ness, David Vesole, Donna Weber, Jan Westin, Keith Wheatley

Research output: Contribution to journalArticle

1675 Citations (Scopus)

Abstract

The monoclonal gammopathies are a group of disorders associated with monoclonal proliferation of plasma cells. The characterization of specific entities is an area of difficulty in clinical practice. The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations. In monoclonal gammopathy of undetermined significance (MGUS) or monoclonal gammopathy, unattributed/unassociated (MG[u]), the monoclonal protein is <30 g/1 and the bone marrow clonal cells <10% with no evidence of multiple myeloma, other B-cell proliferative disorders or amyloidosis. In asymptomatic (smouldering) myeloma the M-protein is ≥ 30 g/1 and/or bone marrow clonal cells ≥ 10% but no related organ or tissue impairment (ROTI)(end-organ damage), which is typically manifested by increased calcium, renal insufficiency, anaemia, or bone lesions (CRAB) attributed to the plasma cell proliferative process. Symptomatic myeloma requires evidence of ROTL Non-secretory myeloma is characterized by the absence of an M-protein in the serum and urine, bone marrow plasmacytosis and ROTI. Solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas (± recurrent) are also defined as distinct entities. The use of these criteria will facilitate comparison of therapeutic trial data. Evaluation of currently available prognostic factors may allow better definition of prognosis in multiple myeloma.

Original languageEnglish (US)
Pages (from-to)749-757
Number of pages9
JournalBritish Journal of Haematology
Volume121
Issue number5
DOIs
StatePublished - Jun 2003
Externally publishedYes

Fingerprint

Paraproteinemias
Plasmacytoma
Multiple Myeloma
Plasma Cells
Bone Marrow Cells
Monoclonal Gammopathy of Undetermined Significance
Bone and Bones
Amyloidosis
Renal Insufficiency
Anemia
Blood Proteins
B-Lymphocytes
Bone Marrow
Urine
Calcium
Proteins
Therapeutics

Keywords

  • Classification
  • Gammopathies
  • Monoclonal
  • Multiple myeloma

ASJC Scopus subject areas

  • Hematology

Cite this

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders : A report of the International Myeloma Working Group. / Kyle, Robert A.; Child, J. Anthony; Anderson, Kenneth; Barlogie, Bart; Bataille, Regis; Bensinger, William; Bladé, Joan; Boccadoro, Mario; Dalton, William; Dimopoulos, Meletios; Djulbegovic, Benjamin; Drayson, Mark; Durie, Brian; Facon, Thiery; Fonseca, Rafael; Gahrton, Gosta; Greipp, Philip; Harousseau, Jean Luc; Harrington, David; Hussein, Mohamad; Joshua, Douglas; Ludwig, Heinz; Morgan, Gareth; Oken, Martin; Powles, Raymond; Richardson, Paul; Roodman, G. David; San Miguel, Jesus; Shimizu, Kazuyuki; Shustik, Chaim; Sirohi, Bhawna; Sonneveld, Pieter; Tricot, Guido; Turesson, Ingemar; Van Ness, Brian; Vesole, David; Weber, Donna; Westin, Jan; Wheatley, Keith.

In: British Journal of Haematology, Vol. 121, No. 5, 06.2003, p. 749-757.

Research output: Contribution to journalArticle

Kyle, RA, Child, JA, Anderson, K, Barlogie, B, Bataille, R, Bensinger, W, Bladé, J, Boccadoro, M, Dalton, W, Dimopoulos, M, Djulbegovic, B, Drayson, M, Durie, B, Facon, T, Fonseca, R, Gahrton, G, Greipp, P, Harousseau, JL, Harrington, D, Hussein, M, Joshua, D, Ludwig, H, Morgan, G, Oken, M, Powles, R, Richardson, P, Roodman, GD, San Miguel, J, Shimizu, K, Shustik, C, Sirohi, B, Sonneveld, P, Tricot, G, Turesson, I, Van Ness, B, Vesole, D, Weber, D, Westin, J & Wheatley, K 2003, 'Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group', British Journal of Haematology, vol. 121, no. 5, pp. 749-757. https://doi.org/10.1046/j.1365-2141.2003.04355.x
Kyle, Robert A. ; Child, J. Anthony ; Anderson, Kenneth ; Barlogie, Bart ; Bataille, Regis ; Bensinger, William ; Bladé, Joan ; Boccadoro, Mario ; Dalton, William ; Dimopoulos, Meletios ; Djulbegovic, Benjamin ; Drayson, Mark ; Durie, Brian ; Facon, Thiery ; Fonseca, Rafael ; Gahrton, Gosta ; Greipp, Philip ; Harousseau, Jean Luc ; Harrington, David ; Hussein, Mohamad ; Joshua, Douglas ; Ludwig, Heinz ; Morgan, Gareth ; Oken, Martin ; Powles, Raymond ; Richardson, Paul ; Roodman, G. David ; San Miguel, Jesus ; Shimizu, Kazuyuki ; Shustik, Chaim ; Sirohi, Bhawna ; Sonneveld, Pieter ; Tricot, Guido ; Turesson, Ingemar ; Van Ness, Brian ; Vesole, David ; Weber, Donna ; Westin, Jan ; Wheatley, Keith. / Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders : A report of the International Myeloma Working Group. In: British Journal of Haematology. 2003 ; Vol. 121, No. 5. pp. 749-757.
@article{d026ce5de96e4d5cb26dd061c6d39bdc,
title = "Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group",
abstract = "The monoclonal gammopathies are a group of disorders associated with monoclonal proliferation of plasma cells. The characterization of specific entities is an area of difficulty in clinical practice. The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations. In monoclonal gammopathy of undetermined significance (MGUS) or monoclonal gammopathy, unattributed/unassociated (MG[u]), the monoclonal protein is <30 g/1 and the bone marrow clonal cells <10{\%} with no evidence of multiple myeloma, other B-cell proliferative disorders or amyloidosis. In asymptomatic (smouldering) myeloma the M-protein is ≥ 30 g/1 and/or bone marrow clonal cells ≥ 10{\%} but no related organ or tissue impairment (ROTI)(end-organ damage), which is typically manifested by increased calcium, renal insufficiency, anaemia, or bone lesions (CRAB) attributed to the plasma cell proliferative process. Symptomatic myeloma requires evidence of ROTL Non-secretory myeloma is characterized by the absence of an M-protein in the serum and urine, bone marrow plasmacytosis and ROTI. Solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas (± recurrent) are also defined as distinct entities. The use of these criteria will facilitate comparison of therapeutic trial data. Evaluation of currently available prognostic factors may allow better definition of prognosis in multiple myeloma.",
keywords = "Classification, Gammopathies, Monoclonal, Multiple myeloma",
author = "Kyle, {Robert A.} and Child, {J. Anthony} and Kenneth Anderson and Bart Barlogie and Regis Bataille and William Bensinger and Joan Blad{\'e} and Mario Boccadoro and William Dalton and Meletios Dimopoulos and Benjamin Djulbegovic and Mark Drayson and Brian Durie and Thiery Facon and Rafael Fonseca and Gosta Gahrton and Philip Greipp and Harousseau, {Jean Luc} and David Harrington and Mohamad Hussein and Douglas Joshua and Heinz Ludwig and Gareth Morgan and Martin Oken and Raymond Powles and Paul Richardson and Roodman, {G. David} and {San Miguel}, Jesus and Kazuyuki Shimizu and Chaim Shustik and Bhawna Sirohi and Pieter Sonneveld and Guido Tricot and Ingemar Turesson and {Van Ness}, Brian and David Vesole and Donna Weber and Jan Westin and Keith Wheatley",
year = "2003",
month = "6",
doi = "10.1046/j.1365-2141.2003.04355.x",
language = "English (US)",
volume = "121",
pages = "749--757",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders

T2 - A report of the International Myeloma Working Group

AU - Kyle, Robert A.

AU - Child, J. Anthony

AU - Anderson, Kenneth

AU - Barlogie, Bart

AU - Bataille, Regis

AU - Bensinger, William

AU - Bladé, Joan

AU - Boccadoro, Mario

AU - Dalton, William

AU - Dimopoulos, Meletios

AU - Djulbegovic, Benjamin

AU - Drayson, Mark

AU - Durie, Brian

AU - Facon, Thiery

AU - Fonseca, Rafael

AU - Gahrton, Gosta

AU - Greipp, Philip

AU - Harousseau, Jean Luc

AU - Harrington, David

AU - Hussein, Mohamad

AU - Joshua, Douglas

AU - Ludwig, Heinz

AU - Morgan, Gareth

AU - Oken, Martin

AU - Powles, Raymond

AU - Richardson, Paul

AU - Roodman, G. David

AU - San Miguel, Jesus

AU - Shimizu, Kazuyuki

AU - Shustik, Chaim

AU - Sirohi, Bhawna

AU - Sonneveld, Pieter

AU - Tricot, Guido

AU - Turesson, Ingemar

AU - Van Ness, Brian

AU - Vesole, David

AU - Weber, Donna

AU - Westin, Jan

AU - Wheatley, Keith

PY - 2003/6

Y1 - 2003/6

N2 - The monoclonal gammopathies are a group of disorders associated with monoclonal proliferation of plasma cells. The characterization of specific entities is an area of difficulty in clinical practice. The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations. In monoclonal gammopathy of undetermined significance (MGUS) or monoclonal gammopathy, unattributed/unassociated (MG[u]), the monoclonal protein is <30 g/1 and the bone marrow clonal cells <10% with no evidence of multiple myeloma, other B-cell proliferative disorders or amyloidosis. In asymptomatic (smouldering) myeloma the M-protein is ≥ 30 g/1 and/or bone marrow clonal cells ≥ 10% but no related organ or tissue impairment (ROTI)(end-organ damage), which is typically manifested by increased calcium, renal insufficiency, anaemia, or bone lesions (CRAB) attributed to the plasma cell proliferative process. Symptomatic myeloma requires evidence of ROTL Non-secretory myeloma is characterized by the absence of an M-protein in the serum and urine, bone marrow plasmacytosis and ROTI. Solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas (± recurrent) are also defined as distinct entities. The use of these criteria will facilitate comparison of therapeutic trial data. Evaluation of currently available prognostic factors may allow better definition of prognosis in multiple myeloma.

AB - The monoclonal gammopathies are a group of disorders associated with monoclonal proliferation of plasma cells. The characterization of specific entities is an area of difficulty in clinical practice. The International Myeloma Working Group has reviewed the criteria for diagnosis and classification with the aim of producing simple, easily used definitions based on routinely available investigations. In monoclonal gammopathy of undetermined significance (MGUS) or monoclonal gammopathy, unattributed/unassociated (MG[u]), the monoclonal protein is <30 g/1 and the bone marrow clonal cells <10% with no evidence of multiple myeloma, other B-cell proliferative disorders or amyloidosis. In asymptomatic (smouldering) myeloma the M-protein is ≥ 30 g/1 and/or bone marrow clonal cells ≥ 10% but no related organ or tissue impairment (ROTI)(end-organ damage), which is typically manifested by increased calcium, renal insufficiency, anaemia, or bone lesions (CRAB) attributed to the plasma cell proliferative process. Symptomatic myeloma requires evidence of ROTL Non-secretory myeloma is characterized by the absence of an M-protein in the serum and urine, bone marrow plasmacytosis and ROTI. Solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas (± recurrent) are also defined as distinct entities. The use of these criteria will facilitate comparison of therapeutic trial data. Evaluation of currently available prognostic factors may allow better definition of prognosis in multiple myeloma.

KW - Classification

KW - Gammopathies

KW - Monoclonal

KW - Multiple myeloma

UR - http://www.scopus.com/inward/record.url?scp=0038509089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038509089&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2003.04355.x

DO - 10.1046/j.1365-2141.2003.04355.x

M3 - Article

C2 - 12780789

AN - SCOPUS:0038509089

VL - 121

SP - 749

EP - 757

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -